Gerresheimer Ag · XETR:GXI
Gerresheimer — Investor Presentation (2014)
18 slides from Gerresheimer's investor presentation, 2014
Slide 1: Gerresheimer Investor Factbook Q2 2014
Gerresheimer Investor Factbook Q2 2014
Slide 2: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development
Slide 3: Our products are important and convenient solutions for everyday life
Our products are … …important… …and convenient… …solutions for everyday life. 3
Slide 4: Gerresheimer's most comprehensive product portfolio for pharma and healthcare
Gerresheimer’s most comprehensive product portfolio for pharma and healthcare Key facts Leading international manufacturer for the global pharma and healthcare industry Pharmaceutical packaging solutions made of glass and plastic Primary packaging products as well as medical devices for storag
Slide 5: Gerresheimer at a glance
Gerresheimer at a glance Key figures FY 2013 (Financial year ends on November 30) Revenues: EUR 1,265.9m Adjusted EBITDA: EUR 249.8m1 Cash flow from operating activities: EUR 146.7m Employees worldwide: 11,239 Locations worldwide: 47 1 Includes EUR 7.5m in other operating income from fair
Slide 6: We offer complex medical devices and primary pharmaceutical packaging
We offer complex medical devices and primary pharmaceutical packaging Plastics & Devices Primary Packaging Glass Storage and safe drug dosage and administration Storage and transport of liquid and solid drugs Inhalers Ampoules, vials, Insulin pens cartridges Glass syringes Pharma glass bot
Slide 7: Customer-focused organization
Customer-focused organization Started at Dec 1, 2013; Pro-forma figures FY 2013 in EUR m Group revenues in FY 2013: EUR 1,265.9m Plastics & Devices Primary Packaging Glass Life Science Andreas Schütte Uwe Röhrhoff Research Rainer Beaujean Revenues: 561.6 Revenues: 635.4 Rev.: EUR 86.8 adj. EBITDA: 1
Slide 8: Clear focus on pharma and healthcare
Clear focus on pharma and healthcare 83% Pharma and healthcare 11% Revenues 2013 Cosmetics EUR 1,266m 6% Other 8
Slide 9: Global player with strong regional footprint
Global player with strong regional footprint Europe USA 22% Revenues 2013: 58% EUR 1,266m Latin America 3% 17% Asia Regional footprint: More than 45 sites worldwide as of November 30, 2013 Established markets Pharmerging markets (IMS definition) Others 9
Slide 10: Highly attractive end market trends
Highly attractive end market trends Aging of world population Development of healthcare systems in emerging countries Growing number of acute and chronic diseases Accelerating pace in drug development Growth in biotech drugs and generics Outsourcing trend of drug delivery and primary pac
Slide 11: Well-diversified blue-chip customer base
Well-diversified blue-chip customer base Revenues generated with TOP 50 customers Pharma and healthcare Other (FY 2013) in EUR m 64% 61% 434 56% Cumulative 49% share 34% 184 94 63 42 Top 10 11-20 21-30 31-40 41-50 Gerresheimer has close long-term relationships with …with limited dependence on indivi
Slide 12: Gerresheimer provides solutions across all key product categories
Gerresheimer provides solutions across all key product categories Life Science Division Plastics & Devices Primary Packaging Glass Research Diabetes TG Glass Plastic Syringe MG Pharma OTC Liquids and Injec- Glass Product Inhalers Packaging Diagnos- Pens Systems (Type I) Syrups (Type II Tubing Consum
Slide 13: Leading market positions in attractive niche markets
Leading market positions in attractive niche markets Life Division Plastics & Devices Primary Packaging Glass Science Research Inha- Diabetes MG Ampoules, Glass Plastic Syringe Product lation Diagnos- Pens Pharma vials, Tubing Consumables Packaging Systems (DPI)1 tics2 (Type I) cartridges & Equipmen
Slide 14: High barriers to entry support strong market positions
High barriers to entry support strong market positions Technological factors Start-up factors Regulatory environment (FDA & EMA authorities, Adoption of technological know-how difficult Pharmacopeia reference standards, GMP – Good Manufacturing Practices) Extensive customer validation procedur
Slide 15: Gerresheimer stands to benefit from three major pharma trends
Gerresheimer stands to benefit from three major pharma trends Rise of emerging countries Generics trend New devices & growth in specialty pharma 15
Slide 16: Gerresheimer's strategy
Gerresheimer’s strategy Base growth: Existing customers and regions Organic New products for existing growth customers New regions and customers Pharma and healthcare Global market Extension of product leadership Growth offerings/technology positions through Extension of geographic acq
Slide 17: Financial Calendar
Financial Calendar October 8, 2014 Interim Report 3rd Quarter 2014 October 8+9, 2014 Capital Markets Day 2014 17
Slide 18: Investor Relations & Creditor Relations contact details
Investor Relations & Creditor Relations contact details Phone +49 211 6181-257 Fax +49 211 6181-121 E-mail gerresheimer.ir@gerresheimer.com IR website www.gerresheimer.com/ir 18